JP2019519467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519467A5 JP2019519467A5 JP2018549808A JP2018549808A JP2019519467A5 JP 2019519467 A5 JP2019519467 A5 JP 2019519467A5 JP 2018549808 A JP2018549808 A JP 2018549808A JP 2018549808 A JP2018549808 A JP 2018549808A JP 2019519467 A5 JP2019519467 A5 JP 2019519467A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- cells
- tumor
- tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022077992A JP2022116028A (ja) | 2016-03-22 | 2022-05-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
| JP2024002743A JP2024050608A (ja) | 2016-03-22 | 2024-01-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
| JP2025172559A JP2026021351A (ja) | 2016-03-22 | 2025-10-14 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311697P | 2016-03-22 | 2016-03-22 | |
| US62/311,697 | 2016-03-22 | ||
| PCT/US2017/023508 WO2017165473A1 (en) | 2016-03-22 | 2017-03-22 | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077992A Division JP2022116028A (ja) | 2016-03-22 | 2022-05-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519467A JP2019519467A (ja) | 2019-07-11 |
| JP2019519467A5 true JP2019519467A5 (enExample) | 2020-04-30 |
| JP7073270B2 JP7073270B2 (ja) | 2022-05-23 |
Family
ID=59899817
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549808A Active JP7073270B2 (ja) | 2016-03-22 | 2017-03-22 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
| JP2022077992A Pending JP2022116028A (ja) | 2016-03-22 | 2022-05-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
| JP2024002743A Pending JP2024050608A (ja) | 2016-03-22 | 2024-01-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
| JP2025172559A Pending JP2026021351A (ja) | 2016-03-22 | 2025-10-14 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077992A Pending JP2022116028A (ja) | 2016-03-22 | 2022-05-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
| JP2024002743A Pending JP2024050608A (ja) | 2016-03-22 | 2024-01-11 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
| JP2025172559A Pending JP2026021351A (ja) | 2016-03-22 | 2025-10-14 | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11458213B2 (enExample) |
| EP (3) | EP3433238B1 (enExample) |
| JP (4) | JP7073270B2 (enExample) |
| KR (4) | KR20250057132A (enExample) |
| CN (3) | CN114716387B (enExample) |
| AU (1) | AU2017238181B2 (enExample) |
| BR (1) | BR112018069507A2 (enExample) |
| CA (1) | CA3018709A1 (enExample) |
| CL (1) | CL2018002683A1 (enExample) |
| CY (1) | CY1124487T1 (enExample) |
| DK (2) | DK3433238T3 (enExample) |
| ES (2) | ES2972148T3 (enExample) |
| FI (1) | FI3925952T3 (enExample) |
| HR (2) | HRP20240215T1 (enExample) |
| HU (2) | HUE055607T2 (enExample) |
| LT (2) | LT3433238T (enExample) |
| MX (1) | MX384823B (enExample) |
| PH (1) | PH12018502048A1 (enExample) |
| PL (2) | PL3433238T3 (enExample) |
| PT (2) | PT3925952T (enExample) |
| RS (2) | RS62274B1 (enExample) |
| RU (2) | RU2749399C2 (enExample) |
| SA (1) | SA518400103B1 (enExample) |
| SI (2) | SI3433238T1 (enExample) |
| TR (1) | TR201813644T1 (enExample) |
| WO (1) | WO2017165473A1 (enExample) |
| ZA (1) | ZA201806389B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018031809A1 (en) | 2016-08-10 | 2018-02-15 | Cancer Targeted Technology Llc | Chelated psma inhibitors |
| US11147889B2 (en) * | 2016-11-23 | 2021-10-19 | Cancer Targeted Technology Llc | Albumin-binding PSMA inhibitors |
| US20200237936A1 (en) | 2016-12-14 | 2020-07-30 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
| WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| WO2018222778A1 (en) * | 2017-05-30 | 2018-12-06 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| SMT202400439T1 (it) | 2017-12-11 | 2024-11-15 | Univ Muenchen Tech | Ligandi di psma per la formazione di immagini e endoradioterapia |
| EP3494999A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| EP3494998A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Glycosylated psma inhibitors for imaging and endoradiotherapy |
| WO2019115684A1 (en) * | 2017-12-13 | 2019-06-20 | Sciencons AS | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide |
| KR102794330B1 (ko) * | 2018-02-06 | 2025-04-11 | 우니베르시타트 하이델베르크 | Fap 억제제 |
| CA3090495A1 (en) * | 2018-02-06 | 2019-08-15 | The Johns Hopkins University | Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy |
| CA3094620C (en) | 2018-03-30 | 2022-11-22 | Futurechem Co., Ltd. | Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer |
| WO2019240884A2 (en) | 2018-04-27 | 2019-12-19 | University Of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
| JP7500551B2 (ja) * | 2018-09-28 | 2024-06-17 | ウニベルジテート ハイデルベルク | 前立腺特異的膜抗原（ｐｓｍａ）の標識化阻害剤、画像化剤としてのそれらの使用、及びｐｓｍａ発現がんの処置のための医薬剤 |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| KR102403970B1 (ko) * | 2018-12-27 | 2022-05-31 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| CN119101005A (zh) | 2019-07-02 | 2024-12-10 | 诺华股份有限公司 | 前列腺特异性膜抗原（psma）配体及其用途 |
| AU2020299974A1 (en) * | 2019-07-02 | 2022-01-27 | Advanced Accelerator Applications (Italy) Srl | Prostate specific membrane antigen (PSMA) ligands and uses thereof |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
| US20230097381A1 (en) * | 2020-04-24 | 2023-03-30 | Radiomedix, Inc. | Composition, kit and method for diagnosis and treatment of prostate cancer |
| CA3180809A1 (en) * | 2020-04-29 | 2021-11-04 | Novartis Ag | Methods for radiolabelling psma binding ligands and their kits |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| EP4244216A1 (en) | 2020-11-12 | 2023-09-20 | ABX Advanced Biochemical Compounds GmbH | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| US20230414762A1 (en) * | 2020-11-17 | 2023-12-28 | The Johns Hopkins University | Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma |
| ES3053944T3 (en) | 2020-11-19 | 2026-01-28 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| CA3222172A1 (en) * | 2021-06-17 | 2022-12-22 | Mayo Foundation For Medical Education And Research | Methods and materials for combining biologics with multiple chelators |
| KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
| JP2025506001A (ja) | 2022-02-09 | 2025-03-05 | ノバルティス アーゲー | ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 |
| WO2024138060A2 (en) * | 2022-12-21 | 2024-06-27 | Mayo Foundation For Medical Education And Research | Methods and materials for combining biologics with multiple chelators |
| IL326014A (en) | 2023-07-21 | 2026-03-01 | Novartis Ag | PSMA-targeted radioligand treatment regimen |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2926573C (en) * | 2007-06-26 | 2018-08-28 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| US9422234B2 (en) | 2007-11-30 | 2016-08-23 | The Johns Hopkins University | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer |
| BRPI0922839A2 (pt) * | 2008-12-05 | 2019-09-03 | Molecular Insight Pharmaceuticals, Inc. | radiofarmacêuticos específicos de ca-ix para tratamento e imageamento de câncer. |
| PL3222617T3 (pl) * | 2009-03-19 | 2023-01-02 | The Johns Hopkins University | Związki do kierunkowania w psma i ich zastosowania |
| PL2739316T3 (pl) * | 2011-08-05 | 2019-09-30 | Molecular Insight Pharmaceuticals, Inc. | Radioznakowane inhibitory antygenu błonowego specyficznego dla prostaty |
| CN107382890B (zh) * | 2011-11-30 | 2021-01-29 | 约翰霍普金斯大学 | 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途 |
| CA2897437C (en) | 2013-01-14 | 2021-12-14 | Molecular Insight Pharmaceuticals, Inc. | Triazine based radiopharmaceuticals and radioimaging agents |
| EP2862857A1 (en) | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP3456700A1 (en) * | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CA2950892C (en) * | 2014-05-06 | 2023-10-24 | The Johns Hopkins University | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy |
| ES2912753T3 (es) | 2014-08-24 | 2022-05-27 | Max Planck Gesellschaft Zur Foerderung Der Wss | Método para la producción de ésteres activos marcados con 18F y su aplicación ejemplificada por la preparación de un marcador de PET específico de PSMA |
| EP3212610B1 (en) * | 2014-10-30 | 2020-10-28 | Katholieke Universiteit Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
| US11520472B2 (en) * | 2015-09-24 | 2022-12-06 | Mitutoyo Corporation | Inspection program editing environment including integrated alignment program planning and editing features |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2017
- 2017-03-22 RS RS20211071A patent/RS62274B1/sr unknown
- 2017-03-22 CA CA3018709A patent/CA3018709A1/en active Pending
- 2017-03-22 PL PL17771028T patent/PL3433238T3/pl unknown
- 2017-03-22 LT LTEPPCT/US2017/023508T patent/LT3433238T/lt unknown
- 2017-03-22 LT LTEP21177643.0T patent/LT3925952T/lt unknown
- 2017-03-22 SI SI201730908T patent/SI3433238T1/sl unknown
- 2017-03-22 KR KR1020257012794A patent/KR20250057132A/ko active Pending
- 2017-03-22 DK DK17771028.2T patent/DK3433238T3/da active
- 2017-03-22 KR KR1020227015010A patent/KR20220063298A/ko not_active Ceased
- 2017-03-22 PL PL21177643.0T patent/PL3925952T3/pl unknown
- 2017-03-22 US US16/087,395 patent/US11458213B2/en active Active
- 2017-03-22 EP EP17771028.2A patent/EP3433238B1/en active Active
- 2017-03-22 KR KR1020187030310A patent/KR102396307B1/ko active Active
- 2017-03-22 RS RS20240205A patent/RS65188B1/sr unknown
- 2017-03-22 EP EP24153551.7A patent/EP4385981A1/en active Pending
- 2017-03-22 CN CN202210306552.XA patent/CN114716387B/zh active Active
- 2017-03-22 AU AU2017238181A patent/AU2017238181B2/en active Active
- 2017-03-22 JP JP2018549808A patent/JP7073270B2/ja active Active
- 2017-03-22 EP EP21177643.0A patent/EP3925952B1/en active Active
- 2017-03-22 MX MX2018011519A patent/MX384823B/es unknown
- 2017-03-22 HR HRP20240215TT patent/HRP20240215T1/hr unknown
- 2017-03-22 HU HUE17771028A patent/HUE055607T2/hu unknown
- 2017-03-22 DK DK21177643.0T patent/DK3925952T3/da active
- 2017-03-22 BR BR112018069507-6A patent/BR112018069507A2/pt active Search and Examination
- 2017-03-22 RU RU2018133693A patent/RU2749399C2/ru active
- 2017-03-22 HU HUE21177643A patent/HUE065327T2/hu unknown
- 2017-03-22 CN CN202510305793.6A patent/CN120172884A/zh active Pending
- 2017-03-22 PT PT211776430T patent/PT3925952T/pt unknown
- 2017-03-22 TR TR2018/13644A patent/TR201813644T1/tr unknown
- 2017-03-22 KR KR1020237034341A patent/KR20230147751A/ko not_active Ceased
- 2017-03-22 WO PCT/US2017/023508 patent/WO2017165473A1/en not_active Ceased
- 2017-03-22 RU RU2021115958A patent/RU2021115958A/ru unknown
- 2017-03-22 ES ES21177643T patent/ES2972148T3/es active Active
- 2017-03-22 FI FIEP21177643.0T patent/FI3925952T3/fi active
- 2017-03-22 SI SI201731477T patent/SI3925952T1/sl unknown
- 2017-03-22 PT PT177710282T patent/PT3433238T/pt unknown
- 2017-03-22 CN CN201780031580.2A patent/CN109311827B/zh active Active
- 2017-03-22 ES ES17771028T patent/ES2877572T3/es active Active
- 2017-03-22 HR HRP20211386TT patent/HRP20211386T1/hr unknown
-
2018
- 2018-09-21 CL CL2018002683A patent/CL2018002683A1/es unknown
- 2018-09-24 PH PH12018502048A patent/PH12018502048A1/en unknown
- 2018-09-25 SA SA518400103A patent/SA518400103B1/ar unknown
- 2018-09-25 ZA ZA2018/06389A patent/ZA201806389B/en unknown
-
2021
- 2021-09-13 CY CY20211100803T patent/CY1124487T1/el unknown
-
2022
- 2022-05-11 JP JP2022077992A patent/JP2022116028A/ja active Pending
- 2022-08-22 US US17/892,203 patent/US20230015736A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002743A patent/JP2024050608A/ja active Pending
- 2024-12-13 US US18/979,841 patent/US20250195700A1/en active Pending
-
2025
- 2025-10-14 JP JP2025172559A patent/JP2026021351A/ja active Pending